دورية أكاديمية
أعرض في EDS

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.

التفاصيل البيبلوغرافية
العنوان: Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy.
المؤلفون: Guidolin V; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA., Li Y; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA., Jacobs FC; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA., MacMillan ML; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; Blood and Marrow Transplantation & Cellular Therapy Program, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA., Villalta PW; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN 55455, USA., Hecht SS; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA., Balbo S; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.; School of Public Health, University of Minnesota, Minneapolis, MN 55455, USA.
المصدر: Molecular therapy oncolytics [Mol Ther Oncolytics] 2023 Jan 20; Vol. 28, pp. 197-210. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101666776 Publication Model: eCollection Cited Medium: Print ISSN: 2372-7705 (Print) Linking ISSN: 23727705 NLM ISO Abbreviation: Mol Ther Oncolytics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2017- : Cambridge, MA : Cell Press
Original Publication: New York, NY : Nature Publishing Group, [2014]-[2023]
مستخلص: DNA alkylating drugs have been used as cancer chemotherapy with variable outcomes. The establishment of predictive biomarkers to identify patients who will effectively respond to treatment would allow for the development of personalized therapies. As the degree of interaction of alkylating drug with DNA plays a key role in their mechanism of action, our hypothesis is that the measurement of the DNA adducts formed by alkylating drugs could be used to inform patient stratification. Beginning with busulfan, we took advantage of our DNA adductomic approach to characterize DNA adducts formed by reacting busulfan with calf-thymus DNA. Samples collected from six patients undergoing busulfan-based chemotherapy prior to allogeneic hematopoietic cell transplantation were analyzed for the presence of busulfan-derived DNA adducts. Among the 15 adducts detected in vitro , 12 were observed in the patient blood confirming the presence of a large profile of DNA adducts in vivo . Two of the detected adducts were structurally confirmed by comparison with synthetic standards and quantified in patients. These data confirm our ability to comprehensively characterize busulfan-derived DNA damage and set the stage for the development of methods to support personalized chemotherapy.
Competing Interests: The authors declare no competing interests.
(© 2023 The Authors.)
References: Blood. 1999 Dec 1;94(11):3960-2. (PMID: 10627126)
Chem Res Toxicol. 2017 Mar 20;30(3):830-839. (PMID: 28140568)
Cancer Res. 1985 Sep;45(9):4237-43. (PMID: 4028012)
Lancet Haematol. 2016 Nov;3(11):e526-e536. (PMID: 27746112)
Int J Cancer. 2017 Aug 1;141(3):604-613. (PMID: 28437852)
Biol Blood Marrow Transplant. 2009 May;15(5):523-36. (PMID: 19361744)
Data Brief. 2015 Sep 10;5:161-70. (PMID: 26501085)
Pediatr Blood Cancer. 2012 May;58(5):708-14. (PMID: 21793181)
J Am Med Assoc. 1946 Sep 21;132:126-32. (PMID: 20997191)
Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. (PMID: 27481448)
Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923. (PMID: 28766962)
Chem Res Toxicol. 2015 Sep 21;28(9):1850-60. (PMID: 26285869)
Biomolecules. 2021 Feb 27;11(3):. (PMID: 33673538)
Bone Marrow Transplant. 1994 Nov;14(5):759-65. (PMID: 7889009)
Drug Metab Dispos. 1987 May-Jun;15(3):399-402. (PMID: 2886318)
Ann Lab Med. 2014 Jan;34(1):7-14. (PMID: 24422189)
Front Chem. 2019 Oct 24;7:658. (PMID: 31709223)
Biol Blood Marrow Transplant. 2002;8(9):477-85. (PMID: 12374452)
Anal Chem. 2014 Feb 4;86(3):1744-52. (PMID: 24410521)
Bone Marrow Transplant. 1995 Jul;16(1):31-42. (PMID: 7581127)
Clin Cancer Res. 2003 Oct 1;9(12):4465-74. (PMID: 14555520)
Pharmacotherapy. 2008 Dec;28(12):1502-10. (PMID: 19025431)
J Clin Oncol. 2011 Nov 1;29(31):4121-8. (PMID: 21947825)
Chem Res Toxicol. 2019 Apr 15;32(4):773-783. (PMID: 30740971)
ACS Infect Dis. 2020 Jul 10;6(7):1976-1997. (PMID: 32485104)
Mol Cancer Ther. 2017 Feb;16(2):376-387. (PMID: 27903751)
Chem Res Toxicol. 2002 Nov;15(11):1398-406. (PMID: 12437330)
Eur J Clin Pharmacol. 1989;36(5):525-30. (PMID: 2753072)
Chem Res Toxicol. 2017 Jan 17;30(1):388-409. (PMID: 27936622)
Anal Chem. 2015 Dec 1;87(23):11706-13. (PMID: 26509677)
Drug Metab Dispos. 2007 Feb;35(2):306-14. (PMID: 17132762)
Curr Top Med Chem. 2019;19(9):691-712. (PMID: 30931858)
Cancer Sci. 2004 May;95(5):454-8. (PMID: 15132775)
Cancer Res. 1990 Oct 1;50(19):6203-7. (PMID: 2400986)
BMC Vet Res. 2021 Dec 7;17(1):378. (PMID: 34876121)
Ann Intern Med. 2020 Feb 18;172(4):229-239. (PMID: 31958813)
Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69. (PMID: 19611402)
Blood. 1994 Sep 15;84(6):2036-43. (PMID: 8081005)
Blood. 1997 Apr 15;89(8):3055-60. (PMID: 9108427)
Arch Biochem Biophys. 2015 Oct 1;583:96-104. (PMID: 26278353)
Biochemistry. 2016 Aug 23;55(33):4720-30. (PMID: 27490699)
Anal Chem. 2010 May 1;82(9):3650-8. (PMID: 20361772)
معلومات مُعتمدة: P30 CA077598 United States CA NCI NIH HHS; R50 CA211256 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: DNA adduct; alkylating agents; biomarker; busulfan; mass spectrometry; precision medicine
تواريخ الأحداث: Date Created: 20230223 Latest Revision: 20230523
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9938526
DOI: 10.1016/j.omto.2023.01.005
PMID: 36820303
قاعدة البيانات: MEDLINE
الوصف
تدمد:2372-7705
DOI:10.1016/j.omto.2023.01.005